Dermira Inc. (Nasdaq: DERM) reported disappointing results from two Phase 3 trials of olumacostat glasaretil in patients nine years of age and older with moderate to severe acne vulgaris. The stock price crashed $16.57 to close at $8.59.
Dermira reports disappointing trial results
March 05, 2018 at 18:52 PM EST
